ALT
Altimmune Inc
NASDAQ: ALT · HEALTHCARE · BIOTECHNOLOGY
$2.60
-1.14% today
Updated 2026-04-30
Market cap
$511.15M
P/E ratio
—
P/S ratio
12,467.17x
EPS (TTM)
$-1.00
Dividend yield
—
52W range
$3 – $8
Volume
4.1M
Altimmune Inc (ALT) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-111,127.00%
ROE
-50.60%
ROA
-28.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $1.85M | $1.02M | 100.00% | 65.13% | 55.01% |
| 2007 | $14.64M | $-13.59M | 100.00% | -112.70% | -92.79% |
| 2008 | $32.91M | $-36.42M | 100.00% | -107.09% | -110.65% |
| 2009 | $27.55M | $-32.28M | 100.00% | -94.28% | -117.17% |
| 2010 | $20.99M | $-34.85M | 100.00% | -112.19% | -166.00% |
| 2011 | $24.27M | $-3.80M | 100.00% | -48.32% | -15.65% |
| 2012 | $25.18M | $-4.92M | 100.00% | -24.89% | -19.54% |
| 2013 | $17.91M | $-11.72M | 100.00% | -60.51% | -65.42% |
| 2014 | $10.19M | $-9.96M | 58.15% | -100.01% | -97.70% |
| 2015 | $10.64M | $-3.44M | 52.41% | -31.98% | -32.34% |
| 2016 | $5.23M | $193.85M | -38.07% | -215.37% | 3,706.44% |
| 2017 | $41503.00 | $-46.43M | -44,249.39% | -125,401.20% | -111,860.32% |
| 2018 | $10.33M | $-39.17M | -78.68% | -414.61% | -379.16% |
| 2019 | $5.80M | $-20.52M | 100.00% | -370.00% | -353.71% |
| 2020 | $8.19M | $-49.04M | -309.40% | -669.50% | -599.20% |
| 2021 | $4.41M | $-97.09M | 100.00% | -2,197.60% | -2,201.59% |
| 2022 | $-68000.00 | $-84.71M | 100.00% | 129,029.41% | 124,577.94% |
| 2023 | $426000.00 | $-88.45M | 100.00% | -22,518.54% | -20,762.21% |
| 2024 | $20000.00 | $-95.06M | 100.00% | -515,860.00% | -475,295.00% |
| 2025 | $41000.00 | $-88.09M | -173.17% | -230,460.98% | -214,860.98% |